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ABSTRACT
Background Coronary heart disease (CHD) risk inversely associates with levels of high-density lipoprotein
cholesterol (HDL-C). The protective effect of HDL is thought to depend on its functionality, such as its ability to
induce cholesterol efflux.
Materials and methods We compared plasma cholesterol efflux capacity between male familial hyperc-
holesterolaemia (FH) patients with and without CHD relative to their non-FH brothers, and examined HDL
constituents including sphingosine-1-phosphate (S1P) and its carrier apolipoprotein M (apoM).
Results Seven FH patients were asymptomatic and six had experienced a cardiac event at a mean age of
39 years. Compared to their non-FH brothers, cholesterol efflux from macrophages to plasma from the FH
patients without CHD was 16  22% (mean  SD) higher and to plasma from the FH patients with CHD was
7  8% lower (P = 003, CHD vs. non-CHD). Compared to their non-FH brothers, FH patients without CHD
displayed significantly higher levels of HDL-cholesterol, HDL-S1P and apoM, while FH patients with CHD dis-
played lower levels than their non-FH brothers.
Conclusions A higher plasma cholesterol efflux capacity and higher S1P and apoM content of HDL in
asymptomatic FH patients may play a role in their apparent protection from premature CHD.
Keywords Apolipoprotein M, cholesterol efflux, familial hypercholesterolaemia, high-density lipoprotein,
sphingolipids, sphingosine-phosphate.
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Introduction
Familial hypercholesterolaemia (FH), predominantly caused
by mutations in the low-density lipoprotein (LDL) receptor
gene, is characterized by a severely increased risk of coro-
nary heart disease (CHD) [1]. FH patients with high levels of
high-density lipoprotein cholesterol (HDL-C) are relatively
protected from early development of CHD comparable to the
effect of high HDL-C in the general population [2,3]. It is
known that the atheroprotective effect of HDL is not simply
related to absolute HDL-C levels. For instance, genetic vari-
ants or drugs that raise plasma HDL-C levels not always lead
to CHD risk reduction [4,5]. One of the key roles of HDL is
in reverse cholesterol transport by facilitating cholesterol
efflux from macrophages and returning cholesterol to the
liver for clearance [6,7]. In two large population-based stud-
ies with around 3000 participants each, cholesterol efflux
capacity was inversely associated with the incidence of car-
diovascular events [8,9]. Evidence from epidemiological
studies suggests that the protective role of HDL in the
development of atherosclerosis might be due to its content of
the bioactive sphingolipid sphingosine-1-phosphate (S1P)
[10–15]. S1P as well as its carrier apolipoprotein M (apoM)
mediate many of the beneficial effects of HDL [10,14,16–18].
ApoM is important for the formation of nascent HDL and for
HDL-mediated cholesterol efflux [19,20]. Both HDL S1P levels
and polymorphisms in APOM have been correlated with
CHD risk [19–21].
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In the present study, we investigated whether the capacity of
plasma to induce cholesterol efflux from macrophages is asso-
ciated with residual CHD risk in FH patients. To minimize
variability of genetic and environmental factors, we selected
sib-pairs, consisting of an FH patient and his non-FH brother.
In addition, we investigated whether differences in HDL com-
position are associated with different CHD risk among these
FH patients.
Materials and methods
Study population
Heterozygous male FH patients with a known mutation in the
LDLR or APOB-100 gene, not participating in an intervention
study and having at least one brother without FH were selected
for this study. Twenty FH patients were approached, of whom
five patients and two brothers refused to participate because of
logistic reasons. A total of 13 sib-pairs were included, of whom
seven FH patients had no symptoms of CHD while the other six
had developed symptomatic CHD. Therefore, the final selection
was as follows: seven sib-pairs consisted of an FH patient
without CHD and a brother with neither FH nor CHD; the
other six pairs consisted of an FH patient with CHD and a
brother with neither FH nor CHD (Fig. 1). To reduce the
influence of environmental factors, we asked all participants to
quit their medication six weeks prior to blood sampling and to
refrain from smoking in the week before blood sampling [22].
Blood was sampled after fasting overnight and was placed on
ice immediately; plasma was prepared as soon as possible and
stored at 80 °C until further experiments.
The medical ethical committee of the Erasmus MC approved
the protocol and all participants gave written informed consent.
Cholesterol efflux experiments
Cholesterol efflux experiments were performed as described
previously [23]. THP-1 cells, a human monocyte-cell line, were
cultured in RPMI 1640 medium supplemented with 10% foetal
calf serum, 2 mmol/L glutamine and 100 IU/L penicillin/
streptomycin at 37 °C and 5%CO2 in air. Cells were plated into
24-wells plates (250 000 cells/well) and differentiation into
macrophages was induced by treatment for 72 hwith 50 ng/mL
phorbol 12-myristate 13-acetate. Subsequently, cells were incu-
bated for 24 h with 05 lCi/mL [3H]cholesterol in RPMI med-
ium supplemented with 02% fatty acid free bovine serum
albumin (BSA). Then, cells werewashed three timeswith 03 mL
phosphate-buffered saline supplemented with 02% BSA. [3H]-
cholesterol efflux was determined by incubating cells for 4 h at
37 °C in acceptor medium, which consisted of RPMI supple-
mented with heparin (125 units/mL) and 2% (v/v) plasma.
Plasma from an unrelated healthy volunteer without FH and
CHD was used as reference, and medium supplemented with
02% (w/v) BSAwas used as a control for basal efflux. At the end
of the incubation, cell-free medium was collected and cells were
dissolved in 01 M NaOH. Radioactivity in medium and cells
was counted by liquid scintillation spectrometry. The ratio
between radioactivity in medium and radioactivity in cells plus
medium was taken as cholesterol efflux capacity. The mean of
four wells treated with the same plasma or control medium was
taken. All experiments were repeated three times.
Cholesterol, triglyceride and pre-b HDL levels
Plasma cholesterol, HDL-C and triglyceride levels were mea-
sured using a COBAS Mira analyzer (Roche Diagnostics,
Indianapolis, IN, USA). LDL-C was calculated using the
Friedewald formula. Pre-b HDL levels were measured using
the commercially available ELISA kit by Daiichi Pure Chemi-
cals (Tokyo, Japan).
Lipoprotein profiles and apolipoprotein levels
Lipoprotein profiles were obtained using density gradient
ultracentrifugation [24]. KBr (035 g/mL plasma) was added to
plasma to obtain a density of 126 g/mL. Of this plasma, 1 mL
was placed in an ultracentrifuge tube and 19 mL of KBr solu-
tions of 121, 110, 1063, 104 and 102 g/mL in physiological salt
were layered successively on top, followed by 1 mL of water.
Samples were centrifuged at 207 000 g for 18 h at 4 °C using a
SW41 rotor in a L-70 Beckman ultracentrifuge (Beckman
Instruments, Indianapolis, IN, USA). Thereafter, the density
gradient was fractionated from the bottom into 250 lL fractions.
Fractions with densities ranging from 1125–121 g/mL and
1062–1125 g/mL were considered to constitute HDL3 and
HDL2, respectively [25]. Cholesterol, triglyceride, apoA-I and
apoA-II in the fractions were measured using a Selectra E (DDS
Figure 1 Study design. Seven sib-pairs consisted of one FH
and one non-FH brother, both without CHD. Six pairs consisted
of one brother with FH and CHD, the other without FH and CHD.
FH, familial hypercholesterolaemia; CHD, coronary heart
disease.
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Diagnostic system). ApoM was measured by a specific human
apoM ELISA [26].
Sphingosine-1-phosphate levels
Sphingosine-1-phosphate levels in the density gradient fractions
were quantified by a modified LC-MS/MS method described in
detail previously [27]. In brief, 50 lL methanol containing C17-
S1P (113 nmol/L; Avanti Polar Lipids, Alabaster, AL, USA) was
added to 25 lL fraction (from the 250 lL fractions derived from
ultracentrifugation as described above), or to S1P standards
(Avanti Polar Lipids) in KBr solution (density of 102 and
121 g/mL). The mixture was incubated on ice for 30 min and
centrifuged for 30 min at 18 000 g at 4 °C. Of the clear super-
natant, 15 lL was injected onto an Agilent 1200SL system (Agi-
lent Technology, Amstelveen, the Netherlands) and run through
a Xterra C18 column (21 9 10 mm, 35 lm, Waters Chro-
matography, Etten-Leur, the Netherlands) at 40 °C. The elution
started with 1 min of 50% mobile phase B (10% water, 025%
formic acid, 25 mM ammoniumformate in methanol) in mobile
phase A (10% methanol, 025% formic acid, 25 mM ammonium
formate in water), followed by a linear gradient from 50% to 90%
B in A for 6 min, and finally 100% B for 3 min. The flow rate was
set at 025 mL/min and total run time was 14 min.
The effluent was directed to an Agilent 6410 triple quadruple
mass spectrometer and analysed in positive ion mode following
electrospray ionization. The MS/MS transitions of S1P m/z 380
? 264, and of C17-S1P m/z 366? 250 were quantified by taking
the ratios of the integrated peaks.
Statistical analyses
General characteristicswere analysedusingANOVA and chi square
test. Cholesterol efflux experiments were normalized according
to results with plasma from the unrelated healthy volunteer. The
percentage difference between the FH patient and his non-FH
brother was compared between sib-pairs with andwithout CHD
using an independent t-test. The differences in lipid levels, sph-
ingolipid levels and apolipoprotein levels between FH patients
with and without CHDwere analysed by linear regression
adjusted for the value in the brother without FH.
Results
All brothers with FH had a confirmed pathogenic LDL-receptor
or apoB100 gene mutation while all brothers without FH tested
negative (Table S1). At the moment of blood sampling, the
average age of the FH patients without CHD was 41 years
(range 23–65) and of FH patients with CHD was 51 years
(range 49–63). However, the average age of the FH patients
without CHD was similar to the mean age at which the FH
patients with CHD had their first cardiac event (39 years; range
27–52; P = 085). Six out of seven FH patients without CHD
were current or former smokers; three of them had refrained
from smoking for at least 10 years at the time of sampling
(Table 1). Five out of the six FH patients with CHD smoked at
the time of event and all but one quitted at least 10 years before
sampling. All current smokers admitted that they had smoked
a few cigarettes the week prior to blood sampling even though
they were asked not to. The FH patients used cholesterol-low-
ering medication ranging from simvastatin 40 mg to atorvas-
tatin 80 mg with ezetimibe 10 mg. This medication was
stopped for 6 weeks prior to blood sampling.
As expected, the FHpatients had significantly higher total and
LDL-cholesterol (LDL-C) levels than their non-FH sibs (Table 1).
Levels of HDL-C and triglyceride were not significantly differ-
ent between the FH subjects and their respective non-FH sibs.
There was a trend towards higher HDL-C levels in FH patients
without CHD than in FH patients with CHD compared to their
respective non-FH brothers (paired analysis P = 0076). The
mean pre-bHDL level in FH subjects was 49 lg/mL (SD 15) and
in non-FH subjects 40 lg/mL (SD 13; P = 013). In paired anal-
yses, the difference between FH patients without and FH
patients with CHD was not significant (P = 020).
Cholesterol efflux experiments
Plasma from six out of seven FH patients without CHD
induced more cholesterol efflux from cholesterol-loaded
macrophages than plasma from their non-FH sibs. In contrast,
plasma from four out of six FH patients with CHD induced less
efflux than that of their non-FH sibs (Fig. 2a). The mean paired
difference in cholesterol efflux between FH patient and his non-
FH brother was +16% (SD 22%) for the pairs without CHD and
7% (SD 8%) in the pairs with an affected FH patient (analysis
of pairs without vs. with CHD, P = 003; Fig. 2b). These dif-
ferences in efflux were independent of baseline values and
within-pair differences of HDL-C, LDL-C levels, as these dif-
ferences remained statistically significant when these co-vari-
ables were included in a multiple linear regression analysis
(data not shown). Overall cholesterol efflux was slightly, but
non-significantly, higher in the pairs with CHD in comparison
with those without.
Lipoprotein profiles
Analyses of the full lipoprotein profiles revealed differences in
the distribution of cholesterol within the HDL subfractions and
within the LDL subfractions (full profiles shown in Fig. S1a).
In comparison with their non-FH brothers, the FH subjects
without CHD had significantly higher HDL-C in the HDL
fractions of medium and low density (Fig. 3a). Levels of apoA-I
were highest in HDL of all FH patients without CHD (FH
patients without CHD 12 g/L, their non-FH brothers as well as
the FH patients with CHD 09 g/L, their brothers without FH
10 g/L), while levels of apoA-II were not different between FH
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Table 1 General characteristics
Sib-pair of FH patient without CHD
(n = 7) Sib-pair of FH patient with CHD (n = 6)
FH FH+CHD FH FH+CHD+
Age 41  13 41  16 46  8 51  8
Age at event 39  10
Smoking ever 2 6 4 5
Current smoking 1 2 1 1
Total cholesterol [mmol/L] 55  09† 77  20† 59  07* 83  18*
LDL-C [mmol/L] 39  08¶ 60  21¶ 45  07* 69  19*
HDL-C[mmol/L] 139  033 142  038 119  026 115  012
Triglycerides [mmol/L] 112  053 124  045 135  032 105  038
Pre-b HDL [lg/mL] 43  19 51  21 38  45‡ 47  47‡
HDL3-C (mmol/L) 105  014 087  013 070  009 074  009
HDL2-C (mmol/L) 047  006 043  004 025  002 034  002
HDL3 S1P (AU/L) 717  106 827  177 733  056 690  083
HDL2 S1P (AU/L) 217  097 276  105 113  021 126  043
FH, familial hypercholesterolaemia; CHD, coronary heart disease; AU, arbitrary units.
All FH patients were ‘off’ statin treatment.
Values are mean  SD.
†P = 0035, ¶P = 0008, *P = 0025, ‡P = 0006.
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Figure 2 Difference in cholesterol efflux
from cholesterol-labelled macrophages to
plasma. (a) Individual differences in
cholesterol efflux to plasma from an FH
patient and his non-FH brother as a
percentage of the efflux to plasma of the
non-FH sib taken as 100%. Some lines (No
CHD two, CHD four) almost completely
overlap. (b) Percentages difference in
cholesterol efflux when compared to the
brother without FH. FH, familial
hypercholesterolaemia; CHD, coronary
heart disease.
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patients without CHD and their non-FH sibs (since fractions
were pooled per group, no P-value for paired analysis avail-
able; pooled data shown in Fig. S1b,c).
S1P and apoM
Sphingosine-1-phosphate levels in plasma were not different
between the groups. Upon density gradient centrifugation, S1P
was predominantly present in the HDL3 subfractions (Fig. 3b).
Among the four groups, HDL3-S1P levels were highest in the
FH patients without CHD; HDL3-S1P levels were comparable
in the other three groups. Plasma apoM levels were 30% higher
in FH patients without CHD than in their non-FH sibs
(P = 0015; Fig. 3d), whereas there was no significant difference
between FH patient with CHD and their brothers. When mea-
sured in the HDL3 subfractions from the density gradient with
pooled fractions per group, apoM was much higher in FH
patients without than with CHD (Fig. 3c); HDL3-apoM was
comparable among the three other groups.
Correlation of HDL composition and cholesterol
efflux capacity
Cholesterol efflux capacity was not significantly correlated with
pre-b HDL levels (Pearson correlation coefficient 04, P = 02).
Similarly, no correlation was found between cholesterol efflux
capacity and HDL-C, HDL2-C, HDL3-C or apoA-I levels, nor
with plasma apoM levels or HDL3–S1P levels.
Discussion
Compared to their non-FH brothers, the cholesterol efflux
capacity of plasma from FH patients without CHD was higher
than that of patients who already had experienced a cardiac
event. In addition, HDL composition differed with more S1P
and apoM in HDL3 of the FH patients without CHD. Our data
suggest that FH patients with relatively higher cholesterol
efflux capacity of plasma and higher levels of HDL3-bound S1P
and apoM are relatively protected from a cardiac event.
Two recent large population-based studies in 2924 partici-
pants of the Dallas Heart Study and 3494 participants of the
EPIC-Norfolk study [8,9] reported cholesterol efflux capacity
being an independent risk indicator of cardiovascular events.
Earlier smaller studies did not all confirm this association [28–
30]. Differences in outcome may be explained by the methods
used. In the first two large studies, J774 macrophages were used
with stimulatedABCA1 expression, while the other studies used
other cell types with or without regulated ABCA1 expression.
Because we used THP-1 cells with a low ABCA1 expression, we
cannot directly compare our data with these studies.
(a)
(d)
(b) (c)
Figure 3 Levels of cholesterol (a), S1P in high-density lipoprotein (HDL) (b) and apoM (c), and apoM in plasma (d). In c, apoM was
measured in all separate HDL density fractions that were pooled from all individuals in each group. In d, apoM plasma
concentrations were measured in each individual, and values in each familial hypercholesterolaemia patient were connected to his
respective brother. Data are expressed as % of an unrelated control pool plasma.
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In our study, differences in cholesterol efflux capacity among
all individuals did not correlate with differences in HDL-C,
HDL-apoA-I or pre-b-HDL levels. This is in line with earlier
studies showing that cholesterol efflux capacity of plasma not
merely depends on the amount of HDL cholesterol [5,8,31,32],
but may be due to additional differences in composition of
HDL. A previous study in normocholesterolaemic subjects
undergoing coronary angiography suggested that HDL2 is
most important for cholesterol efflux capacity of plasma.
Interestingly, in a study comparing young (13–29 years) FH
patients without symptomatic CHD with healthy individuals,
HDL2 from FH patients appeared to be less efficient in induc-
ing cholesterol efflux [33,34]. One could argue that the higher
amount of HDL2 in the FH patients without CHD in our study
might compensate for this lower functionality. We chose to use
whole plasma in order to reflect the in vivo situation as closely
as possible while net cholesterol efflux from tissues also
depends on the presence of apoB-containing lipoproteins. We
cannot exclude the possibility that differences in cholesterol
efflux we identified were due to differences in cholesterol efflux
to LDL or very-low-density lipoprotein VLDL.
The higher, although nonsignificantly, levels of apoB-con-
taining lipoproteins may explain the higher overall cholesterol
efflux capacity of the brother from the families with CHD [35].
However, additional experiments on a limited number of
samples using apoB-depleted plasma showed similar results as
using whole plasma (data not shown).
Evidence from epidemiological studies indicates that the
protective role of HDL in the development of atherosclerosis is
largely due to its content of the bioactive sphingolipid, S1P
[13–18]. HDL of FH patients without CHD contained higher
amounts of S1P and its carrier molecule apoM, particularly in
HDL3. In a recent study in gestational diabetes mellitus,
cholesterol efflux capacity was shown to be decreased in par-
allel with plasma apoM [36]. This is in line with our finding and
together suggests a link between apoM and cholesterol efflux
capacity and CHD risk. However, we did not find a significant
correlation of cholesterol efflux capacity and differences in
levels of HDL-bound S1P and apoM between FH patients
without and with CHD.
Differences in HDL-S1P as well as apoM might also reflect
functional differences not related to the cholesterol efflux
pathway. S1P and apoM mediate many of the beneficial car-
diovascular effects attributed to HDL such as vascular integrity
and vasorelaxation [10,14,16–18,21]. We did not study these
additional pathways.
The strength of the current study design is that by including
non-FH brothers, molecular and genetic heterogeneity were
diminished as far as possible. Comparable HDL-C levels
between brothers suggest we succeeded in this aim [37].
Limitations of this study include, firstly, the limited number
of subjects, thereby limiting statistical power. However, this
also led to the advantage that all samples could be tested in a
single efflux experiment, eliminating inter-experiment vari-
ability. Secondly, two of the FH patients in the non-sympto-
matic group may have been too young to have had a cardiac
event. However, they were in the age range in which one of the
symptomatic FH patients developed his first event. Moreover,
as a group the nonsymptomatic FH patients were at the mean
age of first event in the symptomatic group. Lastly, due to
recent developments, we chose to focus on S1P and apoM, out
of all components and apolipoproteins present in HDL. To
further unravel mechanisms underlying the differences in
cholesterol efflux reflecting differences in HDL dynamics, it
would be interesting to measure activity of, for example, cho-
lesteryl ester transfer protein (CETP), ATP-binding cassette
transporter A1 (ABCA1) and scavenger receptor class B mem-
ber 1 (SR-BI) in the subfractions. We measured CETP levels in
serum but did not find significant differences (data not shown).
However, it would be of interest to separate HDL2 and HDL3
here as well.
In conclusion, we have shown that plasma from FH patients
without CHD has a higher cholesterol efflux capacity than
plasma from FH patients with CHD, in comparison to their
respective non-FH brothers. This may explain why these FH
patients appear to be protected against CHD despite their
high LDL-cholesterol levels. The observed higher efflux
capacity may involve differences in composition of HDL
including cholesterol, S1P and apoM levels. Increased S1P
levels in HDL might also point at differences in HDL func-
tionality other than cholesterol efflux capacity. These data
suggest that CHD risk in FH patients is modulated by familial
factors not related to the LDL-receptor locus that modulate
the composition of HDL and the effectiveness of reverse
cholesterol transport.
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